654 related articles for article (PubMed ID: 28701396)
1. Effects of the NEDD8-Activating Enzyme Inhibitor MLN4924 on Lytic Reactivation of Kaposi's Sarcoma-Associated Herpesvirus.
Chang PJ; Chen LW; Chen LY; Hung CH; Shih YJ; Wang SS
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701396
[TBL] [Abstract][Full Text] [Related]
2. Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression.
Gjyshi O; Roy A; Dutta S; Veettil MV; Dutta D; Chandran B
J Virol; 2015 Aug; 89(15):7874-92. PubMed ID: 25995248
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of KAP1 enhances hypoxia-induced Kaposi's sarcoma-associated herpesvirus reactivation through RBP-Jκ.
Zhang L; Zhu C; Guo Y; Wei F; Lu J; Qin J; Banerjee S; Wang J; Shang H; Verma SC; Yuan Z; Robertson ES; Cai Q
J Virol; 2014 Jun; 88(12):6873-84. PubMed ID: 24696491
[TBL] [Abstract][Full Text] [Related]
4. Genome-Wide Identification of Direct RTA Targets Reveals Key Host Factors for Kaposi's Sarcoma-Associated Herpesvirus Lytic Reactivation.
Papp B; Motlagh N; Smindak RJ; Jin Jang S; Sharma A; Alonso JD; Toth Z
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541837
[TBL] [Abstract][Full Text] [Related]
5. The single RBP-Jkappa site within the LANA promoter is crucial for establishing Kaposi's sarcoma-associated herpesvirus latency during primary infection.
Lu J; Verma SC; Cai Q; Robertson ES
J Virol; 2011 Jul; 85(13):6148-61. PubMed ID: 21507979
[TBL] [Abstract][Full Text] [Related]
6. Kaposi's sarcoma-associated herpesvirus reactivation is regulated by interaction of latency-associated nuclear antigen with recombination signal sequence-binding protein Jkappa, the major downstream effector of the Notch signaling pathway.
Lan K; Kuppers DA; Robertson ES
J Virol; 2005 Mar; 79(6):3468-78. PubMed ID: 15731241
[TBL] [Abstract][Full Text] [Related]
7. NEDDylation is essential for Kaposi's sarcoma-associated herpesvirus latency and lytic reactivation and represents a novel anti-KSHV target.
Hughes DJ; Wood JJ; Jackson BR; Baquero-Pérez B; Whitehouse A
PLoS Pathog; 2015 Mar; 11(3):e1004771. PubMed ID: 25794275
[TBL] [Abstract][Full Text] [Related]
8. Full-Length Isoforms of Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Accumulate in the Cytoplasm of Cells Undergoing the Lytic Cycle of Replication.
Garrigues HJ; Howard K; Barcy S; Ikoma M; Moses AV; Deutsch GH; Wu D; Ueda K; Rose TM
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978712
[TBL] [Abstract][Full Text] [Related]
9. Sp3 Transcription Factor Cooperates with the Kaposi's Sarcoma-Associated Herpesvirus ORF50 Protein To Synergistically Activate Specific Viral and Cellular Gene Promoters.
Chen LY; Chen LW; Peng KT; Hung CH; Chang PJ; Wang SS
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641483
[TBL] [Abstract][Full Text] [Related]
10. ARID3B: a Novel Regulator of the Kaposi's Sarcoma-Associated Herpesvirus Lytic Cycle.
Wood JJ; Boyne JR; Paulus C; Jackson BR; Nevels MM; Whitehouse A; Hughes DJ
J Virol; 2016 Oct; 90(20):9543-55. PubMed ID: 27512077
[TBL] [Abstract][Full Text] [Related]
11. De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
Ye J; Gradoville L; Daigle D; Miller G
J Virol; 2007 Sep; 81(17):9279-91. PubMed ID: 17596302
[TBL] [Abstract][Full Text] [Related]
12. X box binding protein XBP-1s transactivates the Kaposi's sarcoma-associated herpesvirus (KSHV) ORF50 promoter, linking plasma cell differentiation to KSHV reactivation from latency.
Wilson SJ; Tsao EH; Webb BL; Ye H; Dalton-Griffin L; Tsantoulas C; Gale CV; Du MQ; Whitehouse A; Kellam P
J Virol; 2007 Dec; 81(24):13578-86. PubMed ID: 17928342
[TBL] [Abstract][Full Text] [Related]
13. Identification of Novel Kaposi's Sarcoma-Associated Herpesvirus Orf50 Transcripts: Discovery of New RTA Isoforms with Variable Transactivation Potential.
Wakeman BS; Izumiya Y; Speck SH
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795414
[TBL] [Abstract][Full Text] [Related]
14. BET-Inhibitors Disrupt Rad21-Dependent Conformational Control of KSHV Latency.
Chen HS; De Leo A; Wang Z; Kerekovic A; Hills R; Lieberman PM
PLoS Pathog; 2017 Jan; 13(1):e1006100. PubMed ID: 28107481
[TBL] [Abstract][Full Text] [Related]
15. Acetylation of the latency-associated nuclear antigen regulates repression of Kaposi's sarcoma-associated herpesvirus lytic transcription.
Lu F; Day L; Gao SJ; Lieberman PM
J Virol; 2006 Jun; 80(11):5273-82. PubMed ID: 16699007
[TBL] [Abstract][Full Text] [Related]
16. Kaposi's Sarcoma-Associated Herpesvirus Reactivation by Targeting of a dCas9-Based Transcription Activator to the ORF50 Promoter.
Elbasani E; Falasco F; Gramolelli S; Nurminen V; Günther T; Weltner J; Balboa D; Grundhoff A; Otonkoski T; Ojala PM
Viruses; 2020 Aug; 12(9):. PubMed ID: 32867368
[TBL] [Abstract][Full Text] [Related]
17. Sirtuin 6 Attenuates Kaposi's Sarcoma-Associated Herpesvirus Reactivation by Suppressing Ori-Lyt Activity and Expression of RTA.
Hu M; Armstrong N; Seto E; Li W; Zhu F; Wang PC; Tang Q
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651359
[TBL] [Abstract][Full Text] [Related]
18. Induction of Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen by the lytic transactivator RTA: a novel mechanism for establishment of latency.
Lan K; Kuppers DA; Verma SC; Sharma N; Murakami M; Robertson ES
J Virol; 2005 Jun; 79(12):7453-65. PubMed ID: 15919901
[TBL] [Abstract][Full Text] [Related]
19. Kaposi's sarcoma-associated herpesvirus terminal repeat regulates inducible lytic gene promoters.
Izumiya Y; Algalil A; Espera JM; Miura H; Izumiya C; Inagaki T; Kumar A
J Virol; 2024 Feb; 98(2):e0138623. PubMed ID: 38240593
[TBL] [Abstract][Full Text] [Related]
20. CCAAT/enhancer-binding protein-alpha is induced during the early stages of Kaposi's sarcoma-associated herpesvirus (KSHV) lytic cycle reactivation and together with the KSHV replication and transcription activator (RTA) cooperatively stimulates the viral RTA, MTA, and PAN promoters.
Wang SE; Wu FY; Yu Y; Hayward GS
J Virol; 2003 Sep; 77(17):9590-612. PubMed ID: 12915572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
